

(pursuant to Article 11 of the Japanese Patent Law)

To: Commissioner of the Patent Office

1. International Application Classification: PCT/JP03/04841

2. Applicant

Name: TEIJIN LIMITED

Address: 6-7, Minamihommachi 1-Chome,  
Chuo-ku, Osaka-shi, OSAKA  
541-0054 JAPAN

Nationality: JAPAN

Country of Residence: JAPAN

3. Representative

Name: Hideko MIHARA, Patent Attorney (9967)

Address: c/o Teijin Intellectual Property Center Limited  
1-1, Uchisaiwaicho 2-Chome,  
Chiyoda-ku, TOKYO 100-0011 JAPAN

4. Object of the Amendment:

Specification and Claims

5. Content of the Amendment

(1) "R<sup>1</sup>" appearing on the 4th line of page 15 of the specification (in Japanese) should be amended to "the substituents of R<sup>1</sup>".

(2) "hydrogen" appearing on the 5th line of page 15 of the specification should be deleted.

(3) "R<sup>1</sup>" appearing on the 23rd line of page 557 of the claims should be amended to "the substituents of R<sup>1</sup>".

(4) "hydrogen" appearing on the 23rd line of page 557 of the claims should be deleted.

6. List of Attached Documents

(1) Specification, page 15

(2) Claims, page 557

p15

...

(23) A compound according to any one of (17) to (22) wherein the substituents of R<sup>1</sup> in formula (I) above may be the same or different and each is independently a halogen, hydroxy, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkoxy, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C<sub>1</sub>-C<sub>6</sub> alkyl adduct thereof.

(24) A pharmaceutical composition with CCR3 antagonism, which comprises as an effective ingredient thereof a compound represented by formula (I) above according to any one of (1) to (23), a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C<sub>1</sub>-C<sub>6</sub> alkyl adduct thereof.

(25) A prophylactic and/or therapeutic composition for a disease associated with CCR3, which comprises as an effective ingredient thereof a compound represented by formula (I) above according to any one of (1) to (23), a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C<sub>1</sub>-C<sub>6</sub> alkyl adduct thereof.

(26) A prophylactic and/or therapeutic composition according to (25), wherein said condition is an allergic condition.

(27) A prophylactic and/or therapeutic composition according to (26), wherein said allergic condition is bronchial asthma, allergic rhinitis, atopic dermatitis, urticaria, contact dermatitis or allergic conjunctivitis.

(28) A prophylactic and/or therapeutic composition according to (25), wherein said condition is inflammatory bowel disease.

(29) A prophylactic and/or therapeutic composition according to (25), wherein said condition is AIDS (Acquired Immune Deficiency Syndrome).

(30) ...

...

21. A compound according to any one of claims 17 to 20, wherein  $R^4$  and  $R^5$  in formula (I) may be the same or different and each is independently hydrogen, a halogen, hydroxy, cyano, nitro, carboxyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_7$  alkoxy carbonyl,  $C_2$ - $C_7$  alkanoylamino,  $C_1$ - $C_6$  alkylsulfonyl, amino, carbamoyl,  $C_2$ - $C_7$  N-alkylcarbamoyl, sulfamoyl or  $C_1$ - $C_6$  N-alkylsulfamoyl, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable  $C_1$ - $C_6$  alkyl adduct thereof.

22. A compound according to any one of claims 17 to 20, wherein  $R^4$  and  $R^5$  in formula (I) may be the same or different and each is independently a halogen, hydroxy, cyano, nitro,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_7$  alkoxy carbonyl,  $C_1$ - $C_6$  alkylsulfonyl or  $C_1$ - $C_6$  N-alkylsulfamoyl, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable  $C_1$ - $C_6$  alkyl adduct thereof.

23. (Amended) A compound according to any one of claims 17 to 22 wherein the substituents of  $R^1$  in formula (I) above may be the same or different and each is independently a halogen, hydroxy, cyano, nitro,  $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkoxy, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable  $C_1$ - $C_6$  alkyl adduct thereof.

24 ...